Recent advancements in the treatment of chronic myelogenous leukemia Review uri icon

Overview

MeSH Major

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive

abstract

  • Chronic myelogenous leukemia (CML) is a clonal hematopoetic stem cell disorder characterized by the Philadelphia chromosome and resultant production of the constitutively activated Bcr-Abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem cell transplantation, with stem cell transplantation being the only curative therapy. Through rational drug development, STI571, a Bcr-Abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product targeted therapy, offering new hope for expanded treatment options for patients with CML.

publication date

  • March 9, 2002

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1146/annurev.med.53.082901.103853

PubMed ID

  • 11818480

Additional Document Info

start page

  • 369

end page

  • 81

volume

  • 53